Thorax 2012;67(Suppl 2):A1-A204 A147 completed the study. At Day 21, QVA149 significantly improved exercise endurance time by 59.5 seconds versus placebo (p=0.006), which was of a similar magnitude to the improvement seen with tiotropium versus placebo (66.3 seconds; p=0.002). More patients stopped exercise due to dyspnoea with placebo (43% versus 36% with both QVA149 and tiotropium) and due to muscle fatigue with QVA149 and tiotropium (44-46% versus 38% with placebo). QVA149 also produced significant and clinically meaningful improvements in trough FEV 1 , dynamic IC at exercise isotime, trough IC and trough FVC versus placebo and tiotropium ( Introduction QVA149 is a novel inhaled once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist NVA237 (glycopyrronium) in development for the maintenance treatment of COPD. This study evaluated the effect of QVA149 on
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Rajendra Mehta: he has no conflicts of interest. Introduction QVA149 is a novel once-daily fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237) in development for the treatment of chronic obstructive pulmonary disease (COPD). The BRIGHT study evaluated the effects of QVA149 versus placebo and tiotropium on exercise tolerance and lung function in patients with moderate-to-severe COPD. Methods In a double-blind, double-dummy, 3-period crossover study, patients with moderate-to-severe COPD were randomised to QVA149 110/50 µg, placebo or tiotropium 18 µg once daily for 3 weeks. The primary endpoint was exercise endurance time for QVA149 versus placebo during a submaximal exercise tolerance test (SMETT) via cycle ergometry at Day 21. Dynamic inspiratory capacity (IC) at isotime during exercise, trough IC, trough FEV 1 and trough forced vital capacity (FVC) were also measured. Results Eighty five patients were randomised; mean age was 62 years, mean post-bronchodilator FEV 1 56% predicted. 86% patients
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